New York:Researchers, including one of Indian-origin, have documented the persistence of antibodies that target SARS-CoV-2 in hundreds of patients with Covid-19 at least three months after symptom onset.
"These antibodies could be detected at similar levels in both blood and saliva suggests that saliva could be used as an alternative biofluid for antibody testing," said study authors, including those from Harvard University in the US.
In the first study, Anita Iyer and her team measured antibody responses in the blood of 343 patients with Covid-19 for up to 122 days after symptom onset -- and compared these responses to those of 1,548 control individuals sampled before the pandemic.
The researchers focused only on antibodies specific to the SARS-CoV-2 spike protein's receptor-binding domain.
Read also:Antibodies with potential to block COVID-19 virus identified
To provide a baseline, the researchers estimated sensitivities of IgG, IgA, and IgM antibody types at 95 per cent, 90 per cent and 81 per cent, respectively, for detecting infected individuals between 15 to 28 weeks after symptom onset.
Among these antibodies, spike protein-specific IgM and IgA were short-lived, dropping beneath detection levels at around 49 and 71 days, respectively, after the appearance of symptoms.